Aspen Pharmacare HoldingsJSE:APN +0.66%73 FCF Margin % is 11.58% as of Dec. 2025, which is 84% above its 10-year median of 6.28. GuruFocus rates JSE:APN with a GF Score™ of 73/100 and a GF Value™ of R178.17 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 958 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks better than 62.42% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:APN vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (JSE:APN) has a FCF Margin % of 11.58% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aspen Pharmacare Holdings and its competitors. This is 84% above median its historical median of 6.28. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #360 out of 958 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Aspen Pharmacare Holdings' FCF Margin % too high?
Aspen Pharmacare Holdings' current FCF Margin % of 11.58% is 84% above median its 10-year median of 6.28. The Drug Manufacturers industry median FCF Margin % is 2.45. Aspen Pharmacare Holdings' value of 11.58% is 373.6% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #360 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #360 out of 958 companies for FCF Margin %. This puts Aspen Pharmacare Holdings in the upper half of its industry. The industry median FCF Margin % is 2.45. Aspen Pharmacare Holdings' value of 11.58% is 373.6% above this benchmark. While the company's 10-year median is 6.28 vs. the industry median of 2.45, Aspen Pharmacare Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current FCF Margin % of 11.58% is 373.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current FCF Margin % is 11.58%, which is 84% above median its own 10-year median of 6.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R178.17, compared to a current price of R154.85 — trading 13.1% below its estimated fair value. The current FCF Margin % is 11.58%, which is 84% above median its 10-year median of 6.28 and 373.6% above the Drug Manufacturers industry median of 2.45. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current FCF Margin % is 11.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R154.85 is trading 13.1% below its estimated GF Value™ of R178.17.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
FCF Margin %: 11.58% (84% above median its 10-year median of 6.28)
GF Value™: R178.17 vs. price of R154.85 (13.1% below fair value)
Industry Position: 373.6% above the Drug Manufacturers median (#360 of 958)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score
Get the complete analysis for JSE:APN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
